



Gynecologic Cancer InterGroup (GCIG)

Ovarian Cancer Committee

**Sunday, November 17, 2013, 1:00 p.m. – 2:30 p.m.
Room 2+3, UCL Education Centre, London, UK**

Chair: P.Harter Co-Chair: A.Gonzalez

Please sign attendance forms

AGENDA

Welcome & Introductions and COI disclosures

Approval of Minutes: May 2013

RECENTLY PRESENTED TRIALS:

Harter 10'

ICON 6

ICON 7

AGO-OVAR 12

AGO-OVAR 16

CLOSED/ONGOING TRIALS:

Harter 30'

GEICO: GEICO 1204

MRC: ICON 8, MEOC

MITO: MITO 8, MITO 12, MITO 16b, MITO 18

GINECO: SOLO 2, Alienor, EWOC-1

AGO: OVAR 17, PENELOPE, AGO-OVAR 2.21, DESKTOP III

NSGO: NOVA/ENGOT-0v16

NEW CONCEPTS AND TRIALS: (10' each):

Maintenance Olaparib/Bevacizumab in 1st line

I. Ray-Coquard

Maintenance Olaparib/Cediranib in sensitive relapse

J. Ledermann

SCIENTIFIC DISCUSSION:

3-weekly or weekly treatment in primary ovarian cancer (30')

speakers invited (TBA)

ADJOURN